Clinical Pharmacology in Psychiatry: Strategies in Psychotropic Drug Development (Psychopharmacology Series (10))

This book contains the papers from invited lecturers as well as selected contributions presented at the 6th International Meeting on Clinical Pharmacology in Psychiatry (I.M.C.P.P.) held in Geneva, Switzerland, 5-7 June 1991. At this meeting the basic theme of the previous meetings in this series (Chicago 1979, Troms0 1980, Odense 1982, Bethesda 1985, Troms0 1988) was continued, namely, to bridge the gap between experimental development and clinical reality in psychopharmacology. After more than 25 years of intensive research in biological psychiatry, basic understanding of the biological mechanisms underlying major psychiatric diseases has advanced significantly but is still far from complete. Likewise, the hypotheses underlying the development of new psychotropics have been refined and produced a wide spectrum of novel, yet designed compounds. The crucial condition for all progress in this field is reliable, informative clinical testing of new compounds. It is our hope that this book, as a continuation of the earlier publications in this series, provides further evidence of the ongoing interaction between preclinical and clinical scientists, who only together can assure progress in this exciting area of research and clinical practice. Front Matter....Pages I-XIII Molecular Modeling of Neurotransmitter Receptors and Ligands....Pages 1-8 Structure-Function Analysis of the Three β-Adrenergic Catecholamine Receptors....Pages 9-14 Serotonin Receptor Subtypes....Pages 15-25 Developmental Regulation of 5-HT 2 and 5-HT 1c Receptor Gene Expression in Rat Brain....Pages 26-37 Relevance of 5-HT Autoreceptors for Psychotropic Drug Action....Pages 38-51 Brain Serotonin Subsystem Complexity and Receptor Heterogeneity: Therapeutic Potential of Selective Serotonin Agonists and Antagonists....Pages 52-69 Serotonin Receptors and Antipsychotic Drug Action....Pages 70-81 The Third Dopamine Receptor (D 3 ): New Perspectives in Therapeutics....Pages 82-93 PET Examination of Central D 2 Dopamine Receptor Occupancy in Relation to Extrapyramidal Syndromes in Patients Being Treated with Neuroleptic Drugs....Pages 94-100 Dopaminergic and Serotonergic Aspects of Acute Extrapyramidal Syndromes....Pages 101-110 Methods to Facilitate Early Exploratory Testing of Novel Psychopharmacologic Agents in Humans....Pages 111-123 Neuroleptics and Diagnostic Heterogeneity in Relation to Drug Evaluation....Pages 124-130 Residual and Negative Symptoms in Treatment with Neuroleptics....Pages 131-137 Clinical Dosing of Neuroleptics....Pages 138-148 Diagnostic Heterogeneity in Relation to Drug Evaluation: Antidepressants....Pages 149-162 Dose-Effect Relationships for Tricyclic Antidepressants: The Basis for Rational Clinical Testing of New Antidepressants....Pages 163-173 Dose-Effect and Concentration-Effect Relationships with New Antidepressants....Pages 174-189 Therapeutic Potentials of Recently Introduced Antidepressants....Pages 190-198 Role of Genetic Polymorphism in Psychopharmacology — An Update....Pages 199-211 Psychotropic Drug Metabolism and Clinical Monitoring....Pages 212-229 Disposition of the Neuroleptics Perphenazine, Zuclopenthixol, and Haloperidol Cosegregates with Polymorphic Debrisoquine Hydroxylation....Pages 230-237 Phenotypes for Psychotropic Drug Metabolism in the Elderly....Pages 238-245 Analysis of 935 Haloperidol Concentration Measurements Obtained During Routine Drug Monitoring of 134 Patients....Pages 246-252 Power Analysis for Correlation of Plasma Level and Clinical Data....Pages 253-264 Back Matter....Pages 265-268 This book contains the papers from invited lecturers as well as selected contributions presented at the 6th Int. Meeting on Clinical Pharmacology in Psychiatry.
After more than 25 years of intensive research in biological psychiatry, basic understanding of the biological mechanisms underlying major psychiatric diseases has advanced significantly but is still far from complete-
Likewise, the hypotheses underlying the developmentof new psychotropics have been refined and produced a wide spectrum of novel, yet designed compounds.
This book will provide further evidence of the ongoing interaction between preclinical and clinical scientists,
whoonly together can assure progress in this exciting area of research and clinical practice.